Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Susana Almenara"'
Autor:
Susana Almenara, Beatriz Lozano-Ruiz, Ivan Herrera, Paula Gimenez, Cayetano Miralles, Pablo Bellot, Maria Rodriguez, Jose M. Palazon, Fabián Tarín, Héctor Sarmiento, Rubén Francés, Jose Manuel Gonzalez-Navajas, Sonia Pascual, Pedro Zapater
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 163, Iss , Pp 114885- (2023)
Background: Treatment with non-selective beta-blockers (NSBB) has been associated with anti-inflammatory and anti-cancer effects in patients with cirrhosis. This study aims to analyze the impact of chronic NSBB treatment on immune activation and dise
Externí odkaz:
https://doaj.org/article/83a42d8c1ad84c41bbe259913c18f9f0
Autor:
Pura Ballester, Cristina Espadas, Susana Almenara, Jordi Barrachina, Javier Muriel, Enrique Ramos, Natalia Toral, César Belda, Ana M. Peiró
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 954 (2023)
The long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack of evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 (CYP) 2D6
Externí odkaz:
https://doaj.org/article/97e3abfc873e4da491912cdb3c1d2d06
Autor:
Pablo Zubiaur, Paula Soria-Chacartegui, Dora Koller, Marcos Navares-Gómez, Dolores Ochoa, Susana Almenara, Miriam Saiz-Rodríguez, Gina Mejía-Abril, Gonzalo Villapalos-García, Manuel Román, Samuel Martín-Vílchez, Francisco Abad-Santos
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 133, Iss , Pp 111087- (2021)
Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia, which often causes serious adverse drug reactions. Currently, there are no clinical guidelines implementing pharmacogenetic information on olanzapine. Moreover, t
Externí odkaz:
https://doaj.org/article/de0a772e14e64e7ca07810fe61c423f4
Autor:
Miriam Saiz-Rodríguez, Susana Almenara, Marcos Navares-Gómez, Dolores Ochoa, Manuel Román, Pablo Zubiaur, Dora Koller, María Santos, Gina Mejía, Alberto M. Borobia, Cristina Rodríguez-Antona, Francisco Abad-Santos
Publikováno v:
Biomedicines, Vol 8, Iss 4, p 94 (2020)
Several cytochrome P450 (CYP) CYP3A polymorphisms were associated with reduced enzyme function. We aimed to evaluate the influence of these alleles on the pharmacokinetic parameters (PK) of several CYP3A substrates. We included 251 healthy volunteers
Externí odkaz:
https://doaj.org/article/c81cdbdf79a343f381914fd7c9bcfcbe
Autor:
Peiró, Pura Ballester, Cristina Espadas, Susana Almenara, Jordi Barrachina, Javier Muriel, Enrique Ramos, Natalia Toral, César Belda, Ana M.
Publikováno v:
Pharmaceuticals; Volume 16; Issue 7; Pages: 954
The long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack of evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 (CYP) 2D6
Autor:
Paula Soria-Chacartegui, Francisco Abad-Santos, Dora Koller, Dolores Ochoa, Marcos Navares-Gómez, Manuel Román, Gina Mejía, Susana Almenara, Miriam Saiz-Rodríguez, Pablo Zubiaur
Publikováno v:
Advances in Therapy. 37:3537-3550
Dabigatran is a direct oral anticoagulant (DOAC) used for the treatment of several thrombotic conditions. To date, very few pharmacogenetic studies on dabigatran were published. We aimed to investigate the influence of 59 polymorphisms in 15 genes (i
Autor:
Cristina Espadas, César Belda, Susana Almenara, Víctor Aguilar, Pura Ballester, Javier Muriel, Ana M Peiró, Ana Carolina Londoño, Enrique Albert Pérez
Publikováno v:
AUTISM RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Adults with autism spectrum disorder (ASD) and associated intellectual disability (ID) take a high number of different psychotropic drugs simultaneously. Nowadays, little is known about this multidrug pattern efficacy and safety. The present study ha
Autor:
Samuel Martín, Francisco Abad-Santos, Dora Koller, Marcos Navares-Gómez, Daniel Romero-Palacián, Dolores Ochoa, Miriam Saiz-Rodríguez, Aneta Wojnicz, Manuel Román, Gina Mejía, Pablo Zubiaur, Susana Almenara
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Human Psychopharmacology: Clinical and Experimental
instname
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Human Psychopharmacology: Clinical and Experimental
[Objective] To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment. [Methods] Twenty-four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4102802818529b7929079b25d8aff6b2
http://hdl.handle.net/10261/245439
http://hdl.handle.net/10261/245439
Autor:
Samuel Martín-Vílchez, Paula Soria-Chacartegui, Dolores Ochoa, Miriam Saiz-Rodríguez, Marcos Navares-Gómez, Manuel Román, Francisco Abad-Santos, Gina Mejía-Abril, Pablo Zubiaur, Gonzalo Villapalos-García, Susana Almenara, Dora Koller
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 133, Iss, Pp 111087-(2021)
Biomedicine & Pharmacotherapy
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Biomedicine & Pharmacotherapy
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia, which often causes serious adverse drug reactions. Currently, there are no clinical guidelines implementing pharmacogenetic information on olanzapine. Moreover, t
Autor:
Miriam Saiz-Rodríguez, Gina Mejía, Francisco Abad-Santos, Dora Koller, Manuel Román, Marcos Navares-Gómez, Elena Pintos-Sánchez, Susana Almenara, Elena Santos-Molina, Dolores Ochoa, Pablo Zubiaur
Publikováno v:
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Advances in Therapy
Digital.CSIC. Repositorio Institucional del CSIC
instname
Consejo Superior de Investigaciones Científicas (CSIC)
Advances in Therapy
Digital.CSIC. Repositorio Institucional del CSIC
instname
[Introduction] Aripiprazole and olanzapine are atypical antipsychotics. Both drugs can induce metabolic changes; however, the metabolic side effects produced by aripiprazole are more benign. The aim of the study was to evaluate if aripiprazole and ol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a441e39c104c49203133f437447fcab